The potential development of drug resistance is a common concern during the clinical use of antiviral agents, although our understanding of resistance to many antiviral drugs has come from studying virus mutants selected in cell culture (for a review, see reference 5) . Subsequent investigation of virus isolated from treated individuals has largely substantiated predictions based on laboratory studies as to the likely nature and frequency of resistant virus occurring during treatment (5) . Unfortunately, this approach has not proved useful in the study of human immunodeficiency virus (HIV) resistance to zidovudine (3'-azido-3'-deoxythymidine), as attempts to select resistant strains in cell culture have so far been unsuccessful (15, 21) . However, analysis of HIV obtained from treated individuals revealed that resistance frequently occurs during prolonged use of zidovudine (12) . Isolates may initially become partially resistant at early treatment times and develop increasing resistance as treatment continues (3, 18) . Studies on relatively small patient groups indicate that partially resistant isolates emerge more rapidly when HIV infection is advanced than when treatment is begun during earlier-stage infection (3, 12, 18) . Highly resistant variants have so far been isolated only from treated individuals with late-stage disease (12) .
Resistance is due to mutation in the HIV reverse transcriptase (RT), the target of the triphosphate form of zidovudine (14) . Comparative nucleotide sequence analysis of RT cloned from clinical isolates identified predicted substitutions at four specific amino acid residues associated with resistance (14) . HIV variants were constructed by site-directed mutagenesis with combinations of these mutations in the RT coding region within an infectious molecular clone (HXB2-D) (14) . Virus with all four amino acid changes in RT was highly resistant to zidovudine (HIVRTMC; * Corresponding author.
Asp-67->Asn, Lys-70->Arg, Thr-215->Phe, Lys-219--Gln), whereas a variant with changes in the first three of these residues (HIVRTMC/F) had a partially resistant phenotype (13) . This finding indicates that the highly resistant clinical isolates that we identified with these three specific mutations in RT (but wild type at codon 219) are likely to have an additional mutation (or mutations).
To gain further insight into the initial mutational events occurring during the development of resistance, we have attempted in this study to isolate variants in cell culture by passage of sensitive HIV in zidovudine. We also passaged partially resistant variants in zidovudine with the aim of selecting fully resistant virus which might have gained an additional mutation not previously recognized. We used the sensitive strain HXB2 plus two partially resistant variants (HIVRTMF and HIVRTMC/F), derived from HXB2 by site-directed mutagenesis (the RT mutations in these strains are shown in Table 1 ). The viruses were assessed for sensitivity changes after each passage by quantitative plaque reduction assay in HeLa CD4+ cells (4, 11) . We also used a polymerase chain reaction (PCR) procedure employing selective oligonucleotide primers, which enabled rapid genetic analysis of RT by discrimination of wild-type and mutant residues at each of the four codons of interest (13) .
In this study, we were able to reproduce in vitro the initial order of appearance of resistance mutations seen in HIV clinical isolates (2) . In addition, highly resistant virus selected by passage of the partially resistant variant HIVRTMC/F in zidovudine acquired a novel amino acid substitution at RT codon 219 that conferred the observed additional degree of resistance. value of >1 ,uM. Genetic analysis of RT by selective PCR. DNA was obtained from infected MT-2 cell pellets stored at -70°C by detergent lysis and proteinase K digestion, followed by phenol extraction as detailed elsewhere (13); 1 pLg of this DNA was used directly in each PCR. Selective oligonucleotide primers (with variation at the 3' position) were used in PCR assays paired with common primers, allowing discrimination of wild-type from specific mutant residues at codons 67, 70, 215, and 219 in RT (13) . DNA products of each PCR were analyzed by electrophoresis in 1.5% agarose-Trisborate-EDTA (TBE) gels or composite 3% NuSieve (FMC BioProducts)-1% agarose-TBE gels and visualized by staining with ethidium bromide (1 ,ug/ml).
The mutation to Glu at codon 219 was identified by using the selective primer 4M/E (5'-AGGTTCTTTCTGATGTTT TAC-3') paired with the common primer B (5'-GGATGG AAAGGATCACC-3'). PCR conditions with these primers were identical to those described for primer pairs B +4W and B+4M to discriminate wild type (Lys) from mutant (Gln) at codon 219 (13) . Oligonucleotides were synthesized on an Applied Biosystems 394 machine.
Cloning and nucleotide sequence analysis of RT. The RT coding region was amplified by PCR from MT-2 cell-infected DNA and inserted into the M13 vector mptacl8.1 as described previously (13, 15) . Clones expressing active RT in Escherichia coli were identified and then sequenced by the dideoxynucleotide chain termination method (20) . Specific oligonucleotide primers were used to enable sequence analysis of selected regions of the RT (14) . were infected with HIV from culture supernatants in the presence of gradually increasing amounts of zidovudine ( Table 1 ). The amount of virus recovered in culture supernatants was determined by titration both in MT-2 cells and in the HeLa CD4+ line, HT4-6C. In addition, pellets of infected cells were stored at -70°C for subsequent genetic analysis of virus DNA.
Sensitivity of HIV strains following exposure to zidovudine. Cell-free virus obtained during each passage series was assessed for zidovudine sensitivity by plaque reduction assay in HT4-6C cells. The ID50 values of these isolates from passages 0 to 12 are shown in Fig. 1 . The sensitivity of wild-type HXB2 decreased about 14-fold between passages 4 to 8, with ID50 values increasing from 0.014 ,uM initially to 0.2 ,uM by passage 12. Similarly, the partially resistant variant HIVRTMC/F also decreased in sensitivity during exposure to zidovudine. This change was observed between passages 7 to 11, as the ID50 increased from around 0.4 to 2.5 ,uM. Therefore, highly resistant virus had been derived from HIVRTMC/F through selection pressure with zidovudine. By contrast, little change in sensitivity was seen with HIVRTMF after 12 passages in zidovudine, even though the concentration of drug was increased from 0.1 to 20 ,uM in the MT-2 cell cultures (Table 1) .
Genetic analysis of virus recovered by passage in zidovudine. To determine any genetic changes occurring during passage of HIV in the presence of zidovudine, we analyzed the RT of isolates at every passage by examination of DNA from infected MT-2 cells. This was achieved by using a selective PCR procedure designed to discriminate mutant from wild-type residues at codons 67, 70, 215, and 219 in RT (13) . As expected from the sensitivity data shown in Fig. 1 HIVRTMC/F. These 1.7-kb fragments were cloned into the M13 vector mptacl8.1 (15) , and selected regions were sequenced. This analysis revealed a double-nucleotide change at codon 215 (Thr-bTyr) in HXB2p12 (Table 2) , which was identical to a common mutation observed in clinical isolates after zidovudine treatment (14) . The mixed population identified by selective PCR at codons 67 and 70 was not revealed by sequencing M13 RT clones from HXB2pl2. This was almost certainly because too few clones (in this case four) were analyzed to give reliable information about mixtures of genotypes from this isolate. Nucleotide sequence analysis of RT clones from passage 12 HIVRTMC/F (HIVRTMC/Fpl2) revealed a single change at codon 219 (Lys->Glu). However, this was different from the mutation (Lys-*Gln) seen in clinical isolates at this residue (14) .
Construction by mutagenesis of HIVRTMC/F with Lys->Glu at RT codon 219. It was likely that the mutation at codon 219 (Lys-bGlu) seen in isolate HIVRTMC/Fpl2 conferred increased resistance on this virus. However, to prove that this was the case, we decided to construct a virus based on HIVRTMC/F with this additional mutation in RT. Therefore, the mutation A to G (AAA; Lys-bGAA, Glu) was created in M13 clone RTMC/F by site-directed mutagenesis. Infectious virus was recovered by cotransfection of this clone with the pHXB2-D provirus missing most of the RT region (see Materials and Methods). Virus obtained from this culture (HIVRTMC/F[219E]) was assessed for zidovudine sensitivity by plaque reduction assay in HT4-6C cells ( Table  2) . Introduction of this mutation at codon 219 resulted in a considerable increase in resistance of the virus (ID50 value increased to 4.5 ,uM). This was similar to the increase observed with isolate HWRTMC/Fpl2 recovered by passage in zidovudine and was also similar to the sensitivity of isolate HIVRTMC, which was created previously by mutagenesis with Lys2l9-*Gln (Table 2) .
Application of a selective PCR assay to identify HIV with Glu-219 in RT. In considering the possibility of the Lys-219-*Glu mutation occurring in clinical isolates during treatment, we decided to establish an additional selective PCR assay to identify this change. PCR primer 4M/E was synthesized with the 3' nucleotide complementary to the G residue in mutant codon 219 (GAA). In addition, a deliberate A/A mismatch was designed into this primer at the residue next to the 3' nucleotide to generate greater discrimination of the mutation (13) . Results of the use of primer 4M/E paired with common primer B are shown in Fig. 2 . DNA was extracted from MT-2 cells infected with virus isolates, including HIVRTMC/Fpl2 and HIVRTMC/F[219E], and used in selective PCR whereby primer B was paired separately with either primer 4W, 4M, or 4M/E. PCR products were run on an agarose gel and stained with ethidium bromide (Fig. 2) . A DNA band of the correct size appeared only with primer pair B+4M/E on analysis of isolates HIVRTMC/Fpl2 and HIVRTMC/F[219E]. Isolate HIVRTMC/FpO (before zidovudine passage) was wild type (Lys-219), and the fully resistant mutant HIVRTMC gave a specific PCR band only with primer pair B+4M (indicating Gln-219).
DISCUSSION
The isolation of zidovudine-resistant HIV from individuals during therapy is now well documented (3, 12, 18) . Characterization of these virus isolates has allowed cross-resistance profiles to be determined and the major mutations in RT conferring resistance to be identified (11, 14) . Despite these advances, resistance studies might also be facilitated if systems were available to select HIV mutants in cell culture. Unfortunately, it has so far proved difficult to obtain such HIV strains by passage in zidovudine (15, 21) . The reason for this is unclear, especially as the selection of zidovudineresistant feline immunodeficiency virus in culture has been reported recently (17 In contrast to our observations with passaged wild-type HXB2, in which the mutation identified in RT at codon 215 (Thr--Tyr) is commonly seen in clinical isolates following zidovudine treatment, genetic analysis of the partially resistant strain HIVRTMC/F revealed a novel mutation in RT following zidovudine passage. This mutation at codon 219 was Lys-*Glu in the HIVRTMC/F variant selected in cell culture, whereas the substitution seen at codon 219 in clinical isolates was Lys->Gln (14) . We used site-directed mutagenesis to demonstrate that the Lys-219--Glu mutation in HIVRTMC/F was sufficient to change the virus from partially to highly resistant. In view of the possibility that this mutation might occur in clinical isolates, we adapted the selective PCR procedure to enable screening for such a change in clinical material. It is interesting to speculate on why the variant HIVRTMF, with a Thr--Tyr substitution at codon 215, did not alter significantly in sensitivity during passage in zidovudine. It may have been that the zidovudine concentration used was insufficient to exert pressure to select mutations. Alternatively, the apparent interplay between mutations at codons 70 and 215 during resistance development might require mutations at codon 70 to occur first in order to drive additional mutations.
In summary, we have been able to select HIV variants with increased resistance to zidovudine by passage in cell culture. Wild-type virus behaved similarly to clinical isolates with respect to the nature of mutations in RT and their order of appearance. A partially resistant strain became highly resistant upon passage in zidovudine, but this variant had a novel mutation at codon 219 in RT. It seems likely that another novel mutation(s) in RT has yet to be recognized, although care will be required to prove that any additional mutations seen in the RT of clinical isolates modulate zidovudine resistance. To rule out natural variation, it is essential to carry out site-directed mutagenesis of infectious molecular clones and careful sensitivity analysis of rescued virus. Finally, the passage procedure described here could be applied to investigate the potential development of resistance to other inhibitors of HIV, such as 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. However, it may turn out, as was the case with zidovudine, that the study of clinical isolates from individuals receiving these drugs will give the most rapid insights into sensitivity changes.
